A5058223155- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Human-Animal Interaction Studies
- Neuroendocrine regulation and behavior
- Neuropeptides and Animal Physiology
- Cholinesterase and Neurodegenerative Diseases
- Computational Drug Discovery Methods
- Health, Environment, Cognitive Aging
- Neurological Disease Mechanisms and Treatments
- Machine Learning in Bioinformatics
- Advanced Neuroimaging Techniques and Applications
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Receptor Mechanisms and Signaling
- Protein Hydrolysis and Bioactive Peptides
- Neurological diseases and metabolism
- Neuroinflammation and Neurodegeneration Mechanisms
- Epilepsy research and treatment
- Bipolar Disorder and Treatment
- Cognitive Functions and Memory
- Diet and metabolism studies
- Olfactory and Sensory Function Studies
- Stress Responses and Cortisol
- Pediatric Pain Management Techniques
- Neurogenesis and neuroplasticity mechanisms
- Random Matrices and Applications
Grifols (Spain)
2015-2021
Fundació ACE
2017-2021
Biomedical Research Networking Center on Neurodegenerative Diseases
2021
Instituto de Salud Carlos III
2021
Florey Institute of Neuroscience and Mental Health
2020
Royal Brisbane and Women's Hospital
2020
The University of Melbourne
2020
CSIRO Health and Biosecurity
2020
SOM Biotech (Spain)
2008-2019
Hospital Clínic de Barcelona
2017
We studied usefulness of combining blood amyloid beta (Aβ)42/Aβ40, phosphorylated tau (p-tau)217, and neurofilament light (NfL) to detect abnormal brain Aβ deposition in different stages early Alzheimer's disease (AD).Plasma biomarkers were measured using mass spectrometry (Aβ42/Aβ40) immunoassays (p-tau217 NfL) cognitively unimpaired individuals (CU, N = 591) patients with mild cognitive impairment (MCI, 304) from two independent cohorts (BioFINDER-1, BioFINDER-2).In CU, a combination...
Abstract Introduction Plasma amyloid β (Aβ) peptides have been previously studied as candidate biomarkers to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Methods Free and total Aβ42/40 plasma ratios (FP42/40 TP42/40, respectively) were determined using ABtest assays cognitively normal subjects from the Australian Imaging, Biomarker Lifestyle Flagship Study. This population was followed‐up 72 months their cortical Aβ burden assessed with...
<h3>Objective</h3> To explore whether the plasma total β-amyloid (Aβ) Aβ<sub>42</sub>/Aβ<sub>40</sub> ratio is a reliable predictor of amyloid-PET status by exploring association between these 2 variables in subset Australian Imaging, Biomarkers and Lifestyle (AIBL) study aging cohort. <h3>Methods</h3> Taking samples at 3 separate time points, month 18 (n = 176), 36 169), 54 135), we assessed (TP42/40) with regard to neocortical Aβ burden via PET standardized uptake value (SUVR) investigated...
We investigated the relationship of plasma amyloid beta (Aβ) with cerebral deposition Aβ and tau on positron emission tomography (PET).Forty-four participants (18 cognitively normal older adults [CN], 10 mild cognitive impairment, 16 Alzheimer's disease [AD]) underwent PET a blood draw. Free total Aβ40 Aβ42 were assessed using validated assay. Thirty-seven (17 CN, 8 12 AD) also [18F]flortaucipir scan. Scans preprocessed by standard techniques, mean global regional values extracted. Aβ42/Aβ40...
Immunotherapy targeting the amyloid-β (Aβ) peptide is a promising strategy for treatment of Alzheimer's disease (AD); however, none active or passive vaccines tested have been demonstrated to be effective date. We developed first vaccine against C-terminal end Aβ40, ABvac40, and assessed its safety tolerability in phase I clinical trial. A randomised, double-blind, placebo-controlled, parallel-group, study ABvac40 was conducted with patients aged 50–85 years mild moderate AD. Participants...
The most common animal models currently used for Alzheimer disease (AD) research are transgenic mice that express a mutant form of human Aβ precursor protein (APP) and/or some the enzymes implicated in their metabolic processing. However, these carry own APP and APP-processing enzymes, which may interfere production different amyloid-beta (Aβ) peptides encoded by transgenes. Additionally, genetic backgrounds possible confounding factor with regard to crucial aspects AD they (or not)...
Abstract Background To facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer’s disease, supportive biomarker information is necessary. This study was aimed to investigate the association plasma amyloid-beta (Aβ) levels with presence pathological accumulation Aβ in brain measured by amyloid-PET. Both Aβ42/40 ratio alone or combined an FDG-PET-based neurodegeneration were assessed as potential AD biomarkers. Methods We included 39 cognitively normal...
The present study was aimed at assessing the capability of A β 1-40 and 1-42 levels in undiluted plasma (UP), diluted (DP), cell bound (CB) to distinguish between early stages Alzheimer's disease (AD), amnesic mild cognitive impairment (MCI), healthy control (HC). Four blood samples from each participant were collected during one month determined by a blinded proprietary ELISA sandwich (Araclon Biotech. Zaragoza, Spain). First striking result that amount UP represented only small proportion...
Peripheral biomarkers that identify individuals at risk of developing Alzheimer's disease (AD) or predicting high amyloid beta (Aβ) brain burden would be highly valuable. To facilitate clinical trials disease-modifying therapies, plasma concentrations Aβ species are good candidates for peripheral AD biomarkers, but studies to date have generated conflicting results. The Fundació ACE Healthy Brain Initiative (FACEHBI) study uses a convenience sample 200 diagnosed with subjective cognitive...
Subjective cognitive decline (SCD) has been proposed as a potential preclinical stage of Alzheimer's disease (AD). Nevertheless, the genetic and biomarker profiles SCD individuals remain mostly unexplored.We evaluated apolipoprotein E (APOE) ε4's effect in risk presenting SCD, using Fundacio ACE Healthy Brain Initiative (FACEHBI) cohort Spanish controls, performed meta-analysis addressing same question. We assessed relationship between APOE dosage brain amyloid burden FACEHBI Disease...
Abstract Introduction Blood‐based assays to measure brain amyloid beta (Aβ) deposition are an attractive alternative the cerebrospinal fluid (CSF)–based currently used in clinical settings. In this study, we examined different blood‐based Aβ and how they compare among centers assays. Methods Aliquots from 81 plasma samples were distributed 10 participating centers. Seven immunological four mass‐spectrometric methods concentrations. Results Correlations weak for Aβ42 while Aβ40 correlations...
The Face-Name Associative Memory Exam (FNAME) is a paired associative memory test created to detect deficits in individuals with preclinical Alzheimer's disease (AD). Worse performance on FNAME cognitively healthy were found related higher amyloid beta (Aβ) burden measured Positron-Emission-Tomography using 11C-PiB (PiB-PET). We previously reported normative data of Spanish version (S-FNAME) Spanish-speaking subjects. aim the present study was determine whether S-FNAME associated Aβ...
Abstract Background We assessed the feasibility of plasma Aβ42/Aβ40 determined using a novel liquid chromatography-mass spectrometry method (LC-MS) as useful biomarker PET status in Korean cohort from DPUK Study. Methods A total 580 participants belonging to six groups, Alzheimer’s disease dementia (ADD, n = 134), amnestic mild cognitive impairment (aMCI, 212), old controls (OC, 149), young (YC, 15), subcortical vascular (SVCI, 58), and cerebral amyloid angiopathy (CAA, 12), were included...
Plasma amyloid beta (Aβ) levels are being investigated as potential biomarkers for Alzheimer's disease. In AB128 cross-sectional study, a number of medical relevant correlates blood Aβ40 or Aβ42 were analyzed in 140 subjects (51 disease patients, 53 healthy controls and 36 individuals diagnosed with mild cognitive impairment). We determined the association between multiple variables measured three different compartments called i) Aβ directly accessible (DA) plasma, ii) recovered from plasma...
Many patients suffering late-onset Alzheimer disease show a deficit in respiratory complex IV activity. The de novo pyrimidine biosynthesis pathway connects with the mitochondrial chain upstream from IV. We hypothesized that these would have decreased nucleotide levels. Then, different cell processes for which compounds are essential, such as neuronal membrane generation and maintenance synapses production, be compromised. Using model, we inhibiting oxidative phosphorylation function reduces...
Abstract Plasma amyloid-β peptide concentration has recently been shown to have high accuracy predict plaque burden in the brain. These plasma markers will allow wider screening of population and simplify reduce costs for therapeutic trials Alzheimer’s disease. The aim this study was determine how longitudinal changes blood track with brain amyloid-β. Australian Imaging, Biomarker Lifestyle participants a minimum two assessments were evaluated (111 cognitively normal, 7 mild impaired, 15...